Vectofusin-1 Promotes RD114-TR-Pseudotyped Lentiviral Vector Transduction of Human HSPCs and T Lymphocytes
Ex vivo transduction of human CD34+ hematopoietic stem/progenitor cells (hCD34+ HSPCs) and T lymphocytes is a key process that requires high efficiency and low toxicity to achieve effective clinical results. So far, several enhancers have been used to improve this process. Among them, Retronectin hi...
Main Authors: | Claudia Piovan, Virna Marin, Cinzia Scavullo, Stefano Corna, Erica Giuliani, Sergio Bossi, Anne Galy, David Fenard, Claudio Bordignon, Gian Paolo Rizzardi, Chiara Bovolenta |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-06-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050117300438 |
Similar Items
-
RD-MolPack technology for the constitutive production of self-inactivating lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope
by: Virna Marin, et al.
Published: (2016-01-01) -
Codon Optimization Leads to Functional Impairment of RD114-TR Envelope Glycoprotein
by: Eleonora Zucchelli, et al.
Published: (2017-03-01) -
Vectofusin-1, a New Viral Entry Enhancer, Strongly Promotes Lentiviral Transduction of Human Hematopoietic Stem Cells
by: David Fenard, et al.
Published: (2013-01-01) -
Lentiviral Vector Pseudotypes: Precious Tools to Improve Gene Modification of Hematopoietic Cells for Research and Gene Therapy
by: Alejandra Gutierrez-Guerrero, et al.
Published: (2020-09-01) -
Pseudotyping Lentiviral Vectors: When the Clothes Make the Virus
by: Alexis Duvergé, et al.
Published: (2020-11-01)